1,664 filings
Page 44 of 84
8-K
ya03h
6 Apr 11
Other Events
12:00am
8-K
1dwhmwrf6z7 i71u0sx
4 Apr 11
Other Events
12:00am
8-K
akm6nbi3mrv ho2l8p
29 Mar 11
Other Events
12:00am
8-K
bk9blphy
21 Mar 11
Other Events
12:00am
8-K
tbfq0x
4 Mar 11
European Commission Approves Self-Administration Label for FIRAZYR® (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attacks
12:00am
8-K
srvjbfmwr
2 Mar 11
Other Events
12:00am
8-K
gqeznpv94yc ktg6ap
2 Mar 11
Other Events
12:00am
8-K
ohzelxcsv xebf0m8
28 Feb 11
Shire Files Complete Response to FDA’s Not Approvable Letter for FIRAZYR® (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
12:00am
8-K
ru0 z7m8r22pb
24 Feb 11
Other Events
12:00am
8-K
rqvjry i5sc
10 Feb 11
Results of Operations and Financial Condition
12:00am
8-K
ocd ap9q0a3fuavc
1 Feb 11
Other Events
12:00am
8-K
nhcvtqo8xwq2z39bq
1 Feb 11
Other Events
12:00am
8-K
sq5rg8wk
11 Jan 11
Shire plans to review development pathways with health authorities
12:00am
8-K
llakthtc5wn8qbafdm
4 Jan 11
Other Events
12:00am
8-K
i6s7gi
3 Dec 10
Other Events
12:00am
8-K
gpw93f8ud7r n8
1 Dec 10
Other Events
12:00am
8-K
1ed0nxp
1 Dec 10
Shire Reports Positive Efficacy and Safety Results From FAST-3 Study of FIRAZYR® (icatibant) for Acute Attacks of Hereditary Angioedema
12:00am
8-K
wybyrq
26 Nov 10
Entry into a Material Definitive Agreement
12:00am
8-K
1q1crpp3 t4agjjef9f
24 Nov 10
Other Events
12:00am